Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q3 FY25 Earnings Presentation
27 slides from Mankind Pharma's earnings presentation, Jan 23, 2025
Slide 1: Investor Presentation Q3FY25
ig Mankindil> INVESTOR PRESENTATIO Q3FY25 23 January 2025
Slide 2: Index
Index 03 Additional Information • Key Milestones • Mankind Pharma at a Glance • Key Strengths • Strategy Going Ahead 01 Financial Performance • Expansion in Specialty and Super Specialty • Key Financials – Q3 FY25 Segments • P & L Highlights – Q3 & 9M FY25 • Financials - Steady Growth Trajectory • K
Slide 3: Financial Performance
ig Mankindii> Sirois Life Financial Performance
Slide 4: Q3 FY25 - Key Financial Snapshot
Q3 FY25 - Key Financial Snapshot Financials / Margins Growth Capital Efficiency 3,230 23.9% 11% / 37% Revenue (INR Cr) YoY Growth ROCE / Adj. ROCE2 833 / 25.8% 36.4% 6,739 EBITDA (INR Cr) / Margin YoY Growth Net Debt (INR Cr) 895 / 27.7% 46.5% 2.2x Adj. EBITDA1 / Margin YoY Growth Net Debt / Adj. EB
Slide 5: Q3 & 9M FY25 - P&L Highlights
Q3 & 9M FY25 - P&L Highlights YoY QoQ YoY INR Crore Q3FY25 Q3FY24 Q2FY25 9MFY25 9MFY24 Growth Growth Growth Revenue from Operations 3,230 2,607 23.9% 3,077 5.0% 9,200 7,894 16.5% (A=B+C) Domestic Business (B) 2,773 2,400 15.5% 2,796 -0.8% 8,203 7,348 11.6% i. Domestic Business (ex CH) 2,580 2,251 14
Slide 6: Key Financial Metrics
Key Financial Metrics Cash Flow from Operations (INR crore) CAPEX (INR crore) ROCE1 Q1 Q2 Q3 Q1 Q2 Q3 With BSV Acquisition 344 1,636 1,599 324 37% 34% 91 * 31% 460 * 99 25% 2,152 667 832 128 1,813 593 114 481 389 111 125 11%* 488 546 Mar31, Mar31, Dec31, Dec31, 9MFY24 9MFY25 FY23 FY24 9MFY24 9MFY25
Slide 7: Business Updates
ig Mankindil> Jeroing Life Business Updates
Slide 8: Domestic Business Performance
Domestic Business Performance Strong Growth in Domestic Revenue1 INR Crore 9,522 8,453 7,595 2,400 2,773 * FY22 FY23 FY24 Q3FY24 Q3FY25 Market share has increased from 4.4% in Mar-24 to 4.8%2 as of Dec-24 on account of BSV acquisition aided by leadership in Gynae (# 1 in IPM) Secondary sales gro
Slide 9: Increased chronic share by 200bps in last 12 months
Increased chronic share by 200bps* in last 12 months Consistent focus to increase chronic contribution BSV’s super specialty portfolio Mankind Consolidated 39.1 37.6 38.3 38.6 39.3 34.0 35.8 38.4 38.3 39.3 32.7 34.0 37.6 37.6 37.6 38.3 38.6 35.7 35.6 34.1 17.4 15.4 15.7 15.2 FY23 FY24 Q3FY24 Q3FY25
Slide 10: Q3FY25 – Therapywise Performance
Q3FY25 – Therapywise Performance High Ranks across Acute and Chronic Areas Q3FY25 - Sales Mix representing Diversified Therapy Presence* Rank in CVM* FY 20-24 CAGR 2% Key Therapy Areas 11% (Q3FY25) 14% Mankind IPM Anti-Infectives Cardiovascular Chronic therapies 15% 11% 5% 4% Gastro Intestinal Anti
Slide 11: Building Consumer Healthcare Franchise
Building Consumer Healthcare Franchise Consumer Healthcare Segment Revenue (INR Crore) EBITDA % 19.9% 20.2% 17.2% 2% 692 706 589 149 193 FY22 FY23 FY24 Q3FY24 Q3FY25 Strong revenue growth of 30% YoY in Q3FY25 supported by steady growth across all key brands Strong growth in secondary sales1 for
Slide 12: Strong Corporate Identity Complements Brand Recall…
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Kartik Sunny Radhika Aaryan Leone Apte Market Share – 29% #1 Anushka Kajal Srabanti Pre
Slide 13: Exports Business Update
Exports Business Update Revenue from Exports (INR Crore) 813 457 # 296 187 207 FY22 FY23 FY24 Q3FY24 Q3FY25 Revenue growth of 121% YoY driven by increase in our base business supported by new launches in last 12-24 months and consolidation of BSV# Mankind (excl. BSV) has launched 1 product in Q3
Slide 14: Additional Information
ig Mankindii> Serving Life y/ Additional Information
Slide 15: Key Milestones – Disruption led growth
Key Milestones – Disruption led growth 1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 Entered into in- Acquired 100% stake in licensing agreements BSV Limited Successfully listed Commenced Entered chronic Entered Paonta Sahib Launched dedicated specialty Acquired brands with: on NSE and BSE operat
Slide 16: Mankind Pharma at a Glance - FY24
Mankind Pharma at a Glance - FY24 #1 Youngest #4 4 Rank in Prescriptions over Rank by value in Consumer Healthcare brands in Top 5 of the IPM* Market the last seven years* IPM* ranked #1 in their categories* Leadership INR 10,335 Crore 92% 23 16,000+ Brand families* worth FY24 Revenue FY24 Domestic
Slide 17: Key Strengths
Key Strengths India revenues contribute 92% of total revenues in FY24 Focus on Focus on Consistent CFO/ EBITDA ratio in excess of 80% domestic domestic during FY24 business Volume- Best in class business cash growth driven Consistent outperformance in volume growth vs IPM* conversion by metrics 1 af
Slide 18: Strategy Going Ahead
Strategy Going Ahead Increase the value of prescriptions in existing markets by expanding market coverage; CVM moved from 62% in FY21 to 69% in FY24* Increasing share of chronic segment by growing presence in existing therapies (Diabetes - Insulin Glargine, Respiratory – Inhalers) and expansion into
Slide 19: Consistently Expanding to Specialty and Super Specialty
Consistently Expanding to Specialty and Super Specialty Mankind Pharma Domestic From mass market to consumer to specialty chronic Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty ~INR 1,723 Cr/28% 28% / 36% ~INR 70
Slide 20: Consistently Expanding Our Portfolio Towards Specialty Products
Consistently Expanding Our Portfolio Towards Specialty Products Reference Brand Launched Market 5 Therapy Area Indication Market Size Rationale (Year) (INR Cr) Year CAGR # (2023) • Neptaz – In-licensed from Novartis. Strong Revenue and Volume Heart Failure 6261 21% growth. Ranks in the top 5 in its
Slide 21: Financials - Steady Growth Trajectory
Financials - Steady Growth Trajectory Revenue (INR Cr) Strong Growth in Domestic Revenue Revenue from Exports (INR crore) 15% 13% CAGR CAGR 81% 10,335 CAGR 9,522 813 8,749 8,453 7,782 7,595 5,865 6,214 6,028 5,789 296 186 187 76 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 F
Slide 22: Key Performance Highlights
Key Performance Highlights Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 FY24 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 8.5 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 4.4 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 4 CVM share in total IPM (%) 60.2 61.6 62
Slide 23: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 1.6% 3.4% 7.8% NSE Symbol MANKIND 14.5% Market Cap. (INR Crore)* 1,18,836 % Free Float 27.3 Free Float Market Cap. (INR Crore) 32,435 72.7% Shares Outstanding (Crore) 41.3 Industry Pharmaceuticals Promoters FPI & Bodies Corporate Mutual Funds Retail Others Shar
Slide 24: Annexures
Annexures • ROE = (Profit for the year) / (average total equity less cash) o Profit excludes interest income and gain on current investments measured at FVTPL • ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, tota
Slide 25: Safe Harbour Statement
Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goa
Slide 26: Q3 & 9M FY25 Earnings Call Details
Q3 & 9M FY25 Earnings Call Details Date 24th January, 2025 Time 12:00 noon IST Dial – In Details Universal Access Numbers +91 22 6280 1120 / +91 22 7115 8003 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=5816484&linkSecurityString=27bbde6bf0 26
Slide 27: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Head - Investor Relations 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com